TheWell Bioscience
Pre-clinicalVitroGel® xeno-free hydrogels - Next-generation synthetic extracellular matrix (ECM) driving platforms for precision medicine, cell therapy, and biomanufacturing.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $14.5M
About
VitroGel® xeno-free hydrogels - Next-generation synthetic extracellular matrix (ECM) driving platforms for precision medicine, cell therapy, and biomanufacturing.
Cell TherapyRegenerative Medicine
Funding History
2Total raised:$14.5M
Series A$12MMar 15, 2023
Seed$2.5MJun 15, 2021